# Cliffs

> Cliffs is a VC fund in Luxembourg backing Software, Biotechnology and Artificial Intelligence. See 13 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Luxembourg, Luxembourg
- Total investments: 13
- Last investment: Nov 2025
- Lead investor: 8%
- Last updated: Aug 2026
- X (Twitter): https://twitter.com/CliffsVc
- Website: http://www.cliffs.vc

Cliffs is a global, sector agnostic, technology-focused investment firm, we look at and invest in: Application software, IT infrastructure, Cloud, Security, DevOps, AiOps, Open Source Software and Enterprises SaaS.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 4 | 31% |
| Biotechnology | 4 | 31% |
| Artificial Intelligence | 3 | 23% |
| Computer | 2 | 15% |
| Aerospace | 2 | 15% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 46% |
| Seed | 4 | 31% |
| Series B | 1 | 8% |
| Series C | 1 | 8% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 92% |
| Italy | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Red Queen Bio | Red Queen Bio works with frontier labs to map AI-enabled biothreats and pre-build medical countermeasures against them. | $15M | Seed | Nov 13, 2025 |  |
| Parallel Systems | Parallel Systems designs an autonomous, zero-emissions freight transportation system. The company believes the future of freight transportation should be fast, inexpensive, and clean, while also reducing congestion on the highways. Parallel Systems was founded in 2020 and is headquartered in Los Angeles, California. | $38M | Series B | Apr 14, 2025 |  |
| Quaise Energy | Quaise is an energy company that is developing and commercializing novel millimeter-wave drilling systems to harness geothermal energy around the globe, overcoming the geographic constraints limiting this energy source today. The company was founded in 2018 and is based in Cambridge, Massachusetts. | $21M | Series A | Dec 12, 2023 |  |
| Jellatech | Jellatech is a B2B biotech business based in Raleigh, NC, and with R&D in Wageningen, Netherlands. Jellatech is producing high-quality, pure, animal-free collagen and gelatin. Founded by a group of innovators, dreamers, entrepreneurs, and scientists, Jellatech is eliminating the dependency on animals, to make better ingredient products -starting with collagen and gelatin. | $3.5M | Seed | Aug 22, 2023 |  |
| Machina Labs | Machina Labs is a mechanical & industrial engineering & manufacturing firm that unlocks manufacturing through AI & machine learning. |  | Series A | Feb 15, 2023 |  |
| MemVerge | MemVerge is delivering the world’s first Memory-Converged Infrastructure (MCI) system, built with proprietary Distributed Memory Objects (DMO) technology. DMO technology provides a logical convergence layer that harnesses Intel’s new Optane DC persistent memory to let data-centric workloads run flawlessly at memory speed. |  | Venture - Series Unknown | Dec 28, 2022 |  |
| HelixNano | Helix Nanotechnologies uses artificial intelligence to help cure genetic diseases. HelixNano is a Y Combinator and venture backed biotech startup. At HelixNano, we have spent the last two years developing cancer vaccines. Now we are adapting our synthetic biology arsenal to take on COVID-19. We’re moving fast but thinking long-term. We’re alreadytesting COVID-19 vaccine candidates designed to be precise and safe. Our next goal is to create a vaccine that protects everyone not only from this virus, but all future coronaviruses. | $45M | Series A | Mar 22, 2022 |  |
| Orb Aerospace | Orb Aerospace is a manufacturing company that focuses on developing an electric aircraft to revolutionize the aviation sector. Orb Aerospace was founded in 2017 and was headquartered in Lowell, Michigan. |  | Seed | Mar 22, 2022 |  |
| Olatec Therapeutics | Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Parkinson's and Alzheimer’s disease, spinalcord injury, multiple sclerosis, type-2 diabetes, melanoma, pancreatic and breast cancers, among others.By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands. |  | Series A | Mar 16, 2022 |  |
| Skydweller | Skydweller is a US-Spanish aerospace company developing solar powered aircraft solutions capable of achieving perpetual flight with the highest—and most meaningful—payload capacity. Utilizing technology based upon the longest continuous solar powered flight program in history, our fast-growing startup is developing a new class of unmanned aircraft,providing the persistence of geosynchronous satellites with the powerful sensing capabilities and range of a large, airborne platform. | $40M | Series A | Sep 09, 2021 |  |

10 of 13 investments shown.

## Co-investors
- [Milano Investment Partners SGR](https://shizune.co/investors/profile/milano-investment-partners) — VC Fund, 4 deals together
- [Congruent Ventures](https://shizune.co/investors/profile/congruent-ventures) — VC Fund, 2 deals together
- [Advection Growth Capital](https://shizune.co/investors/profile/advection-growth-capital) — VC Fund, 1 deal together
- [Anthos Capital](https://shizune.co/investors/profile/anthos-capital) — VC Fund, 1 deal together
- [Bill Silva Ventures](https://shizune.co/investors/profile/bill-silva-ventures) — VC Fund, 1 deal together
- [Bluestein Ventures](https://shizune.co/investors/profile/bluestein-associates) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Cliffs invest in?

Cliffs invests primarily in Software, Biotechnology and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cliffs last invest?

The most recent investment recorded for Cliffs closed in Nov 2025. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co